Sage Therapeutics Inc [SAGE] stock prices are up 0.73% to $16.57 at the moment. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The SAGE shares have lost -0.06% over the last week, with a monthly amount drifted -18.57%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 11, April 2024, Sage Therapeutics to Report First Quarter 2024 Financial Results on Thursday, April 25, 2024. In a post published today on Yahoo Finance, Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today announced that it will host a live webcast on Thursday, April 25, 2024 at 8:00 a.m. ET to review first quarter 2024 financial results and discuss recent business updates.
From an analyst’s perspective:
Sage Therapeutics Inc [NASDAQ: SAGE] stock has seen the most recent analyst activity on December 12, 2023, when Deutsche Bank initiated its Hold rating and assigned the stock a price target of $21. Previously, Needham downgraded its rating to Hold on August 08, 2023. On August 08, 2023, downgrade downgraded it’s rating to Neutral but maintained its price target of $22 on the stock. Canaccord Genuity downgraded its rating to a Hold and decreased its price target to $21 on August 08, 2023. Wedbush downgraded its rating to a Neutral and reduced its price target to $22 on August 07, 2023. Stifel downgraded its rating to Hold for this stock on August 07, 2023, and downed its price target to $22. In a note dated August 07, 2023, RBC Capital Mkts downgraded an Sector Perform rating on this stock and revised its target price from $71 to $25.
The stock price of Sage Therapeutics Inc [SAGE] has been fluctuating between $15.88 and $59.99 over the past year. Currently, Wall Street analysts expect the stock to reach $64.67 within the next 12 months. Sage Therapeutics Inc [NASDAQ: SAGE] shares were valued at $16.57 at the most recent close of the market. An investor can expect a potential return of 290.28% based on the average SAGE price forecast.
Analyzing the SAGE fundamentals
The Sage Therapeutics Inc [NASDAQ:SAGE] reported sales of 86.46M for trailing twelve months, representing a surge of 2621.54%. Gross Profit Margin for this corporation currently stands at 0.98% with Operating Profit Margin at -6.71%, Pretax Profit Margin comes in at -6.26%, and Net Profit Margin reading is -6.16%. To continue investigating profitability, this company’s Return on Assets is posted at -0.6, Equity is -0.57 and Total Capital is -0.73. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 16.27 points at the first support level, and at 15.96 for the second support level. However, for the 1st resistance point, the stock is sitting at 16.84, and for the 2nd resistance point, it is at 17.11.
Sage Therapeutics Inc [SAGE] reported earnings per share of -$0.55 for its fiscal quarter that ended on 12/30/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$1.28/share, meaning a difference of $0.73 and a surprise factor of 57.00%. By comparison, the stated earnings for the previous quarter ended on 9/29/2023 were -$3.37 per share as compared to estimates of -$2.73 per share, a difference of -$0.64 representing a surprise of -23.40%.
Ratios To Look Out For
It’s worth pointing out that Sage Therapeutics Inc [NASDAQ:SAGE]’s Current Ratio is 10.51. Also, the Quick Ratio is 10.49, while the Cash Ratio stands at 0.86. Considering the valuation of this stock, the price to sales ratio is 11.52, the price to book ratio is 1.24.
Transactions by insiders
Recent insider trading involved Barrett Elizabeth, Director, that happened on Aug 09 ’23 when 2000.0 shares were purchased. Director, Barrett Elizabeth completed a deal on May 09 ’23 to buy 1000.0 shares.
